ClinicalTrials.gov
Cure8 trial brief
Why This Matters
This trial tests whether an oral S1P modulator (etrasimod) is more effective than standard mesalazine for inducing remission in adults with active UC — a question that could affect initial treatment choices in China.
It also measures symptom relief, deeper tissue healing, biomarkers, and quality of life, which matter to patients hoping for better disease control and daily functioning.
Who Should Pay Attention
Adults with active ulcerative colitis (including newly diagnosed patients), clinicians treating UC, researchers studying S1P modulators or UC therapies, and patients considering options before biologics or small-molecule therapy.
Study Snapshot
Story typeClinical Reference
Trial phasePhase 4
Enrollment320 participants
Study statusNot_yet_recruiting
Source depthTrial registry record
What To Know
This is a ClinicalTrials.gov record for a phase 4 randomized, open-label study comparing etrasimod 2 mg once daily versus mesalazine in ~320 Chinese adults with active ulcerative colitis.
The trial will assess clinical remission at 24 weeks plus endoscopic, biomarker, tissue-healing, quality-of-life, and safety outcomes; participants include newly diagnosed patients and those with inadequate response or intolerance to conventional therapies but naive to biologics and other small molecules.
Treatment lasts 24 weeks with a 4-week safety follow-up; key assessments include endoscopy, biopsies, blood and stool inflammatory markers, and bowel ultrasound. An interim analysis is planned.
Keep In Mind
This is an interventional Phase 4, open-label study conducted in China; while endoscopy readers and pathologists are blinded, patients and treating staff are not. The trial record describes planned methods and outcomes but does not report results. Participation excludes people with prior biologic or small-molecule therapy.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical trial
Evidence type derived from source or registry metadata.
PublicationClinicalTrials.gov
SponsorSir Run Run Shaw Hospital
Trial IDNCT07782242
Study typeInterventional
Trial phasePhase 4
Enrollment320 participants
Indexed viaClinicalTrials.gov
Source typeTrial registry record
PublishedAug 24, 2026, 12:00 AM
Content availableTrial registry record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A National Multicenter Study of Etrasimod for the Treatment of Patients With Active UC
This registry will provide real-world data on how etrasimod is used and performs in routine clinical practice in China, including patient characteristics, symptom trajectories, safety, and healthcare costs. Real-world...
Study of Oral Upadacitinib to Assess Change in Disease Activity in Adult Participants With Ulcerative Colitis
This study will collect real-world data on adults with moderate-to-severe ulcerative colitis who start upadacitinib, tracking symptom remission and imaging response over one to two years — information that can help...
Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease
This press release reports phase 2 evidence that a new experimental antibody (duvakitug) showed clinical, endoscopic, and histologic improvements in both UC and Crohn’s disease, which could lead to a new treatment option...